These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 28949997)
61. Evaluation of compliance to congenital Chagas disease treatment: results of a randomised trial in Bolivia. Chippaux JP; Salas-Clavijo AN; Postigo JR; Schneider D; Santalla JA; Brutus L Trans R Soc Trop Med Hyg; 2013 Jan; 107(1):1-7. PubMed ID: 23296694 [TBL] [Abstract][Full Text] [Related]
62. Electrocardiographic Abnormalities and Treatment with Benznidazole among Children with Chronic Infection by Trypanosoma cruzi: A Retrospective Cohort Study. Colantonio LD; Prado N; Segura EL; Sosa-Estani S PLoS Negl Trop Dis; 2016 May; 10(5):e0004651. PubMed ID: 27158908 [TBL] [Abstract][Full Text] [Related]
63. Time-dependent oxidative stress caused by benznidazole. Pedrosa RC; De Bem AF; Locatelli C; Pedrosa RC; Geremias R; Wilhelm Filho D Redox Rep; 2001; 6(4):265-70. PubMed ID: 11642718 [TBL] [Abstract][Full Text] [Related]
64. Antitrypanosomal therapy for chronic Chagas' disease. Bern C N Engl J Med; 2011 Jun; 364(26):2527-34. PubMed ID: 21714649 [No Abstract] [Full Text] [Related]
65. Association of HLA-B∗35 and moderate or severe cutaneous reactions secondary to benznidazole treatment in chronic chagas disease. Bosch-Nicolau P; Salvador F; Sánchez-Montalvá A; Franco-Jarava C; Arrese-Muñoz I; Sulleiro E; Roure S; Valerio L; Oliveira-Souto I; Serre-Delcor N; Pou D; Treviño B; Aznar ML; Espinosa-Pereiro J; Molina I Clin Microbiol Infect; 2022 Jun; 28(6):881.e1-881.e5. PubMed ID: 34863919 [TBL] [Abstract][Full Text] [Related]
66. Improved completion rates and characterization of drug reactions with an intensive Chagas disease treatment program in rural Bolivia. Tornheim JA; Lozano Beltran DF; Gilman RH; Castellon M; Solano Mercado MA; Sullca W; Torrico F; Bern C PLoS Negl Trop Dis; 2013; 7(9):e2407. PubMed ID: 24069472 [TBL] [Abstract][Full Text] [Related]
67. Population pharmacokinetic modeling of benznidazole in Brazilian patients with chronic Chagas disease. Frade VP; Moreira CHV; Sabino EC; Bedor DCG; Ghilard FR; Oliveira CDL; Sanches C Rev Inst Med Trop Sao Paulo; 2022; 64():e4. PubMed ID: 35137898 [TBL] [Abstract][Full Text] [Related]
68. Improving access to Chagas disease diagnosis and etiologic treatment in remote rural communities of the Argentine Chaco through strengthened primary health care and broad social participation. Sartor P; Colaianni I; Cardinal MV; Bua J; Freilij H; Gürtler RE PLoS Negl Trop Dis; 2017 Feb; 11(2):e0005336. PubMed ID: 28192425 [TBL] [Abstract][Full Text] [Related]
69. Adverse Events Associated with Nifurtimox Treatment for Chagas Disease in Children and Adults. Berenstein AJ; Falk N; Moscatelli G; Moroni S; González N; Garcia-Bournissen F; Ballering G; Freilij H; Altcheh J Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33168612 [TBL] [Abstract][Full Text] [Related]
70. Transbuccal delivery of benznidazole associated with monoterpenes: permeation studies and mechanistic insights. Amaral BR; Argenta DF; Kroth R; Caon T Eur J Pharm Sci; 2020 Feb; 143():105177. PubMed ID: 31812716 [TBL] [Abstract][Full Text] [Related]
71. Lymphocyte Transformation Test (LTT) in Allergy to Benznidazole: A Promising Approach. Marques-Mejías MA; Cabañas R; Ramírez E; Domínguez-Ortega J; Fiandor A; Trigo E; Quirce S; Bellón T Front Pharmacol; 2019; 10():469. PubMed ID: 31164819 [TBL] [Abstract][Full Text] [Related]
72. New chemotherapy regimens and biomarkers for Chagas disease: the rationale and design of the TESEO study, an open-label, randomised, prospective, phase-2 clinical trial in the Plurinational State of Bolivia. Alonso-Vega C; Urbina JA; Sanz S; Pinazo MJ; Pinto JJ; Gonzalez VR; Rojas G; Ortiz L; Garcia W; Lozano D; Soy D; Maldonado RA; Nagarkatti R; Debrabant A; Schijman A; Thomas MC; López MC; Michael K; Ribeiro I; Gascon J; Torrico F; Almeida IC BMJ Open; 2021 Dec; 11(12):e052897. PubMed ID: 34972765 [TBL] [Abstract][Full Text] [Related]
73. Identification of N-benzylacetamide as a major component of human plasmatic metabolic profiling of benznidazole. Marson ME; Altcheh J; Moscatelli G; Moroni S; García-Bournissen F; Mastrantonio GE Eur J Drug Metab Pharmacokinet; 2015 Jun; 40(2):209-17. PubMed ID: 24711214 [TBL] [Abstract][Full Text] [Related]
74. Chagas Disease: Comparison of Therapy with Nifurtimox and Benznidazole in Indigenous Communities in Colombia. Kann S; Concha G; Frickmann H; Hagen RM; Warnke P; Molitor E; Hoerauf A; Backhaus J J Clin Med; 2024 Apr; 13(9):. PubMed ID: 38731093 [No Abstract] [Full Text] [Related]
75. Experimental and Clinical Treatment of Chagas Disease: A Review. Sales Junior PA; Molina I; Fonseca Murta SM; Sánchez-Montalvá A; Salvador F; Corrêa-Oliveira R; Carneiro CM Am J Trop Med Hyg; 2017 Nov; 97(5):1289-1303. PubMed ID: 29016289 [TBL] [Abstract][Full Text] [Related]
76. An α-Gal antigenic surrogate as a biomarker of treatment evaluation in Trypanosoma cruzi-infected children. A retrospective cohort study. Abal M; Balouz V; Lopez R; Giorgi ME; Marino C; Cruz CV; Altcheh J; Buscaglia CA PLoS Negl Trop Dis; 2024 Jan; 18(1):e0011910. PubMed ID: 38236916 [TBL] [Abstract][Full Text] [Related]